Table 1. Baseline patient characteristics and clinicopathological variables in 47 adolescents and young adult patients with cancer of unknown primary.
| Variable | Patients N (%) (N = 47) | Variable | Patients N (%) (N = 47) |
|---|---|---|---|
| Age (years) | CDX2 immunostaining | ||
| Median | 35 | Negative | 14 (29.8%) |
| ≤ 35 | 23 (48.9%) | Positive | 12 (25.5%) |
| > 35 | 24 (51.1%) | Not done | 21 (44.7%) |
| Gender | Neutrophil-lymphocyte ratio | ||
| Female | 30 (63.8%) | Low (≤ 5) | 31 (70.6%) |
| Male | 17 (36.2%) | High (> 5) | 13 (29.4%) |
| Performance status (ECOG) | Lung metastasis | ||
| 0 | 11 (25.6%) | Absent | 25 (53.2%) |
| 1 | 20 (46.6%) | Present | 22 (46.8%) |
| 2 | 10 (23.2%) | Liver metastasis | |
| 3 | 2 (4.6%) | Absent | 29 (61.7%) |
| Number of metastatic sites | Present | 18 (38.3%) | |
| 1 | 11 (23.4%) | Bone metastasis | |
| 2 | 12 (25.5%) | Absent | 31 (66.0%) |
| 3+ | 24 (51.1%) | Present | 16 (34.0%) |
| Histology | Lymph nodes metastasis | ||
| Adenocarcinoma | 33 (70.2%) | Absent | 19 (40.4%) |
| Carcinoma | 6 (12.7%) | Present | 28 (59.6%) |
| Malignant neoplasm | 4 (8.5%) | First line treatment | |
| Squamous cell carcinoma | 2 (4.3%) | FOLFOX/CAPOX/5FU | 11 (23.4%) |
| Other | 2 (4.3%) | Platinum + Taxane | 8 (17.0%) |
| Lactate dehydrogenase (IU/L)- | Gemcitabine based | 8 (17.0%) | |
| Normal (≤ 618) | 25 (58.1%) | Other platinum based | 6 (12.8%) |
| High (> 618) | 18 (41.9%) | Radiation | 4 (8.5%) |
| CK7 immunostaining | Surgery | 4 (8.5%) | |
| Negative | 10 (21.3%) | Other therapy/Unknown | 6 (12.8%) |
| Positive | 28 (59.6%) | Tissue of origin performed | |
| Not done | 9 (19.1%) | No | 21 (44.7%) |
| CK20 immunostaining | Yes | 26 (55.3%) | |
| Negative | 19 (40.4%) | Tissue of origin | |
| Positive | 18 (38.3%) | Primary predicted | 17 (65.4%) |
| Not done | 10 (21.3%) | Primary not predicted | 9 (34.6%) |